DISCONTINUED OPERATIONS

6 Months Ended

Jun. 30, 2013

Discontinued Operations [Abstract]

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS

The Company completed the sale of OralDNA in December 2012 and completed the sale of HemoCue in April 2013. Results of operations for OralDNA, HemoCue and NID have been reported as discontinued operations for the three and six months ended June 30, 2013 and 2012. The Company recorded a $29.2 million receivable, included in prepaid expenses and other current assets, associated with the agreed upon cash on-hand at closing and other customary adjustments, which was received in July 2013 related to the sale of HemoCue.

Discontinued operations, net of taxes, for the three and six months ended June 30, 2013 includes a gain of $13.3 million (including foreign currency translation adjustments, partially offset by income tax expense and transaction costs) associated with the sale of HemoCue. In addition, income from discontinued operations, net of taxes for the six months ended June 30, 2013, includes discrete tax benefits of $19.8 million associated with favorable resolution of certain tax contingencies related to our NID business.

Summarized financial information for the discontinued operations is set forth below:

	Three Months Ended June 30,					Six Months Ended June 30,
	2013			2012		2013		2012
Net revenues	$	2,563		$	28,459	$	27,562	$	56,218
Income from discontinued operations before taxes	21,083			1,635		22,074		4,152
Income tax (expense) benefit	(8,280		)	845		11,017		1,323
Income from discontinued operations, net of taxes	$	12,803		$	2,480	$	33,091	$	5,475

The remaining balance sheet information related to OralDNA and NID was not material at June 30, 2013 and December 31, 2012. The remaining balance sheet information related to HemoCue was not material at June 30, 2013.